Cost-effectiveness analysis of pembrolizumab versus...

Lung Cancer 2019 / 12 Vol. 138

Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater

She, Longjiang, Hu, Huabin, Liao, Mengting, Xia, Xuefeng, Shi, Yin, Yao, Linli, Ding, Dong, Zhu, Youwen, Zeng, Shan, Shen, Liangfang, Huang, Jin, Carbone, David P.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
138
Language:
english
Journal:
Lung Cancer
DOI:
10.1016/j.lungcan.2019.10.017
Date:
December, 2019
File:
PDF, 562 KB
english, 2019
Conversion to is in progress
Conversion to is failed